• SB 431542: Advanced ALK5 Inhibitor Workflows for TGF-β Resea

  2026-05-26

  SB 431542 is a gold-standard ALK5 inhibitor that empowers researchers to dissect TGF-β signaling in disease and regeneration models. This guide unpacks experimental workflows, troubleshooting, and the latest reference innovations, with actionable protocol parameters for maximal reproducibility.

• D-N-Acetylgalactosamine: Technical Guide for Glycoprotein An

  2026-05-26

  D-N-Acetylgalactosamine is a high-purity, water-soluble standard designed for accurate investigation of glycoprotein constituents and glycosylation pathways in neurological research. It is unsuitable for ethanol-based workflows or protocols requiring long-term storage of prepared solutions, making strict protocol adherence critical for reproducible data.

• Mubritinib (TAK 165): Transforming OXPHOS Targeting in Cance

  2026-05-25

  This article dissects Mubritinib’s mitochondrial complex I inhibition, its repurposing for chemotherapy-resistant AML and KSHV-driven primary effusion lymphoma, and provides actionable protocol guidance for translational researchers. By connecting mechanistic insight, literature-backed validation, and strategic workflow advice, we frame Mubritinib (TAK 165) as a next-generation tool for dissecting metabolic vulnerabilities in cancer.

• Cell Cycle Assay Kit (K2263): Deeper Insights for Epigenetic

  2026-05-25

  Discover how the Cell Cycle Assay Kit enables precise analysis of cell cycle phases and apoptosis, with a focus on epigenetic mechanisms and translational cancer research. This article explores advanced applications and protocol nuances for researchers seeking more than routine cell cycle progression analysis.

• WP1066, JAK2/STAT3 Inhibitor: Protocols for Oncology and Bey

  2026-05-24

  WP1066 enables precise JAK2/STAT3 pathway inhibition for robust cancer and regenerative medicine workflows. This guide translates cutting-edge reference research into actionable, optimized protocols—empowering researchers to probe cell signaling, tumor suppression, and immune modulation with rigor.

• Mubritinib (TAK 165): Redefining Mitochondrial Targets in AM

  2026-05-23

  This article examines Mubritinib (TAK 165) as a paradigm-shifting mitochondrial complex I inhibitor, moving beyond its HER2 legacy. We synthesize mechanistic insights, quantitative evidence, and strategic guidance for translational researchers tackling oxidative phosphorylation-dependent malignancies and virally driven cancers. The perspective uniquely bridges molecular pharmacology, workflow optimization, and future translational directions, featuring practical parameters and highlighting APExBIO’s role in advancing the field.

• Senolytic Potential of L. plantarum DS0037 Exosome-like Nano

  2026-05-22

  This study identifies exosome-like nanovesicles from Lactobacillus plantarum DS0037 as potent, selective senolytic and senomorphic agents. Findings highlight their ability to target senescent cells, modulate key gene expression, and improve skin cell function, offering a promising strategy for anti-aging interventions.

• Strategic PI3K Activation: Translational Leverage with 740 Y

  2026-05-22

  This article guides translational researchers through the mechanistic and strategic dimensions of activating the PI3K/AKT pathway with 740 Y-P, a potent PI 3-kinase activator from APExBIO. It synthesizes current evidence on vesicular trafficking, neuronal survival, and cancer research, contrasts with emerging autophagy findings, and delivers actionable workflow recommendations. The discussion uniquely bridges mechanistic insight with practical, protocol-driven guidance and positions 740 Y-P as a tool for innovation beyond typical product literature.

• Palomid 529 (P529): Next-Gen PI3K/Akt/mTOR Inhibition in Can

  2026-05-21

  Explore how Palomid 529 (P529) uniquely targets the PI3K/Akt/mTOR pathway to advance cancer research and neural applications. This article delivers in-depth mechanistic insights and practical assay guidance, distinguishing itself from prior coverage.

• Calpain Inhibitor I, ALLN: Technical Use in Apoptosis and In

  2026-05-21

  Calpain Inhibitor I, ALLN enables precise inhibition of calpain I/II and cathepsin B/L activity in cell and animal models, supporting apoptosis assay and ischemia-reperfusion injury workflows. It is not suitable for diagnostic or medical use, nor for protocols requiring aqueous solubility.

• Probenecid: Advanced Neuroprotection and MDR Reversal Strate

  2026-05-20

  Explore the multidimensional scientific role of Probenecid in neuroprotection and multidrug resistance (MDR) reversal. This article presents an in-depth analysis of 4-(dipropylsulfamoyl)benzoic acid, bridging mechanistic insights with practical assay guidance.

• Bafilomycin A1: Dissecting V-ATPase Inhibition in Host-Patho

  2026-05-20

  Discover how Bafilomycin A1, a potent V-ATPase inhibitor, uniquely empowers researchers to interrogate host-pathogen interactions, mitophagy, and intracellular pH regulation. This article offers advanced insight and translational guidance beyond conventional protocols.

• Nonivamide (Capsaicin Analog): Advanced TRPV1 Cancer Researc

  2026-05-19

  Nonivamide, a capsaicin analog, is redefining TRPV1-based cancer and neuroimmune research by enabling precise control of apoptosis and inflammation in cell and animal models. Its unique pharmacology and robust solubility profile make it a powerful anti-proliferative agent for both in vitro and in vivo workflows.

• Azithromycin, Roxithromycin: Novel Senolytics Targeting Huma

  2026-05-19

  Ozsvari et al. identify azithromycin and roxithromycin as clinically approved antibiotics that function as highly specific senolytic agents, selectively eliminating senescent human fibroblasts. Their findings highlight a robust screening approach leveraging DNA-damage-induced senescence and underscore the therapeutic potential of repurposing existing drugs for aging research.

• Anti-b Modulates mTOR/PPARγ and SREBP1 Pathways in Lipid Dis

  2026-05-18

  This study demonstrates that Anti-b, a novel small molecule, reduces hyperlipidaemia and hepatic steatosis in animal models by suppressing mTOR/PPARγ and mTOR/SREBP1 signaling. The findings elucidate new mechanistic links between mTOR modulation and lipid metabolism, providing a foundation for future therapeutic development.

409 records 14/28 page Previous Next First page 上5页 1112131415 下5页 Last page